Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 16, 2020
Daily News
November 16, 2020
- With Consensus on 13 Topics Delayed by COVID-19, ICH Expected to Restrict Selection of New Topics at Virtual Assembly
November 16, 2020
- Otsuka’s Pharma Sales Grow 6.3% in January-September on Global Brands
November 16, 2020
- “No Comment with Prejudgment” on COVID-19 Shots for Children: Minister
November 16, 2020
- PMDA Reviewing New Safety Risks for Soliris, Venclexta/Noxafil
November 16, 2020
- MHLW to Continue Follow-Up on Veklury’s Safety/Efficacy Info: Official
November 16, 2020
- MHLW Weighs COVID-19 Vaccinations outside Medical Institutions
November 16, 2020
- COVID-19 Vaccinations for HCPs Not Mandatory: Health Minister
November 16, 2020
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…